Detalhe da pesquisa
1.
Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML: a randomized, placebo-controlled study by the ALLG.
Blood;
142(23): 1960-1971, 2023 12 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37647654
2.
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myeloma.
Eur J Clin Pharmacol;
78(12): 1911-1921, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36205743
3.
A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons.
J Psychosoc Oncol;
38(3): 272-292, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31833452
4.
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).
Blood;
126(4): 500-3, 2015 Jul 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25972158
5.
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Blood Cancer J;
14(1): 54, 2024 Mar 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38531863
6.
Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
Leuk Lymphoma;
59(3): 670-678, 2018 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28768446
7.
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Leuk Lymphoma;
59(6): 1514-1516, 2018 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29022836